SGLT2 Inhibitors and the Risk of Hospitalization for Fournier’s Gangrene: A Nested Case–Control Study

SGLT2 Inhibitors and the Risk of Hospitalization for Fournier’s Gangrene: A Nested Case–Control Study

Abstract Introduction Based on post-marketing surveillance, concern has been raised that sodium–glucose cotransporter 2 inhibitors (SGLT2i) may increase the risk of necrotizing fasciitis of the perineum (Fournier’s gangrene, FG). As a result of the low incidence of FG, data from clinical trials may...

Full description

Bibliographic Details
Main Authors: Tongtong Wang, Shrita M. Patel, Anne Hickman, Xinyue Liu, Philip LStJ Jones, Ira Gantz, Carol E. Koro
Format: Article
Language:English
Published: Adis, Springer Healthcare 2020-02-01
Series:Diabetes Therapy
Subjects:
Antihyperglycemic agents
Fournier’s gangrene
Nested case–control study
Sodium–glucose cotransporter 2 inhibitors (SGLT2i)
Type 2 diabetes
Online Access:https://doi.org/10.1007/s13300-020-00771-8

Internet

https://doi.org/10.1007/s13300-020-00771-8

Similar Items